TG Therapeutics, Inc. (LON:0VGI)
37.50
-1.05 (-2.72%)
At close: Mar 14, 2025
TG Therapeutics Revenue
TG Therapeutics had revenue of $120.86M USD in the quarter ending March 31, 2025, with 90.40% growth. This brings the company's revenue in the last twelve months to $386.39M, up 33.54% year-over-year. In the year 2024, TG Therapeutics had annual revenue of $329.00M with 40.80% growth.
Revenue (ttm)
$386.39M
Revenue Growth
+33.54%
P/S Ratio
19.74
Revenue / Employee
$1.14M
Employees
338
Market Cap
5.19B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
Dec 31, 2020 | 152.00K | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
TG Therapeutics News
- 12 days ago - TG Therapeutics: Considering If The Promise Of Accelerated Revenue Growth Is Enough - Seeking Alpha
- 18 days ago - TG Therapeutics: Progress In MS Tempered By High Expectations - Seeking Alpha
- 20 days ago - Price Over Earnings Overview: TG Therapeutics - Benzinga
- 25 days ago - TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 4 weeks ago - TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals - GlobeNewsWire
- 4 weeks ago - IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche - Investor's Business Daily
- 4 weeks ago - TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug - Seeking Alpha
- 6 weeks ago - Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher - Benzinga